DISCOUNT ZERTIFIKAT - GSK PLC Stock

Certificat

DE000PC3VZ34

Market Closed - Boerse Frankfurt Warrants 11:20:33 2024-05-17 am EDT
14.89 EUR +0.20% Intraday chart for DISCOUNT ZERTIFIKAT - GSK PLC
Current month+0.20%
1 month+0.88%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Chart GSK PLC
Chart DISCOUNT ZERTIFIKAT - GSK PLC
Date Price Change
24-05-17 14.89 +0.20%
24-05-16 14.86 +0.07%
24-05-15 14.85 +0.20%
24-05-14 14.82 0.00%
24-05-13 14.82 +0.14%

Real-time Boerse Frankfurt Warrants

Last update May 17, 2024 at 11:20 am EDT

More quotes

Static data

Product typeCertificats Discount
Buy / SellCALL
Underlying GSK PLC
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PC3VZ3
ISINDE000PC3VZ34
Date issued 2024-01-25
Cap 1,300 p
Last trading day 2024-09-20
Maturity 2024-09-20 (126 Days)
Parity 1 : 1
Emission price 14.43
Emission volume N/A
Payment day 2024-09-26
Bonus-
Settlement règlement en espèces
Currency EUR

Technical Indicators

Discount (ask) 28.12 %
Sideways yield 1.922 %
Sideways yield pa 5.566 %
Outperformance point 1,809 p
Break even 1,275.49 €
Highest since issue 14.89
Lowest since issue 14.48
Spread 0.01
Spread %0.07%
Distance Cap 475 p
Distance Cap %+26.76%
Max. earning 0.2864
Max. earning % 1.922 %

Company Profile

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed monoclonal antibodies to help treat different diseases. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes more than 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines include medicines for immune-mediated conditions. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases.
Sector
-
More about the company

Ratings for GSK plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: GSK plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
17.75 GBP
Average target price
20.32 GBP
Spread / Average Target
+14.50%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW